Pharmaceutical Business review

iCo Therapeutics raises $1.14 million in financing

The company intends to use the net proceeds of the offering for general corporate purposes and working capital.

All common shares issued in the private placement will be subject to a four-month hold period, with the exception of 129,000 common shares that are not subject to a trading restriction.